Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17010232 | 0.81 | XDH (0.70) | XDHSLC22A12 | |
| SCHEMBL17010368 | 0.80 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL22364268 | 0.80 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL17010305 | 0.78 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL19092939 | 0.78 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL22364225 | 0.78 | XDH (0.75) | XDHSLC22A12 | |
| SCHEMBL17010212 | 0.77 | XDH (0.72) | XDHSLC22A12 | |
| Hydrochloric Acid SCHEMBL17010214 | 0.77 | XDH (0.97) | XDHSLC22A12 | |
| SCHEMBL17010279 | 0.75 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL17010242 | 0.75 | XDH (0.72) | XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | ACQUIST LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | ACQUIST LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | ACQUIST LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | ACQUIST LLC | 2017-07-13 | — | — | US | disclosed |
| EP-3104861-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | Warrell, Raymond P., Jr. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123003-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | WARRELL RAYMOND P (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123003-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | WARRELL RAYMOND P (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | XDH, OAT, ATIC | XDH 1/4885SLC22A12 264/4885 |
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | XDH, OAT, ATIC | XDH 1/4885SLC22A12 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.